

8 August 2025

Convatec Group Plc
("Convatec" or "the Company")

Director/PDMR Shareholding

Sale of Ordinary Shares

The Company has been notified of the following transaction in relation to Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary shares of 10 pence each in the Company ("Shares").

On 7 August 2025, Karim Bitar sold 1,250,000 Shares. He continues to retain the majority of his shareholding, as well as unvested PSP and LTIP shares. Further information is set out in Convatec's Directors' Remuneration Report.

Karim Bitar said: "I have yesterday sold a minority of my shareholding in Convatec. This follows the announcement about my medical leave of absence and is for personal reasons unconnected with Convatec. I continue to retain a substantial stake in Convatec and believe that the business is in very good shape, with a clear strategy, strong leadership and attractive growth prospects. I have full confidence in my Convatec colleagues and wish them every success through this interim period."

The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further detail.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

| | | | | | | | |
|----------|---|---|--|----------|-----------|--------|-----------|
| 1 | Details of the person discharging managerial responsibilities / person closely associated | | | | | | |
| a) | Name | Karim Bitar | | | | | |
| 2 | Reason for the notification | | | | | | |
| a) | Position/status | Chief Executive Officer and PDMR | | | | | |
| b) | Initial notification /Amendment | Initial notification | | | | | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | | | |
| a) | Name | Convatec Group Plc | | | | | |
| b) | LEI | 213800LS272L4FIDOH92 | | | | | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | | | | | |
| a) | Description of the financial instrument, type of instrument | Ordinary share of 10p each in Convatec Group Plc | | | | | |
| | Identification code | GB00BD3VFW73 | | | | | |
| b) | Nature of the transaction | Sale of Ordinary Shares | | | | | |
| c) | Price(s) and volume(s) | <table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£2.265</td><td>1,250,000</td></tr></table> | | Price(s) | Volume(s) | £2.265 | 1,250,000 |
| Price(s) | Volume(s) | | | | | | |
| £2.265 | 1,250,000 | | | | | | |
| d) | Aggregated information | | | | | | |
| | - Aggregated volume | N/A - single transaction | | | | | |
| | - Price | £2.265 | | | | | |
| e) | Date of the transaction | 7 August 2025 | | | | | |
| f) | Place of the transaction | London Stock Exchange | | | | | |

Contacts

The person responsible for making this announcement is James Kerton, Company Secretary, Convatec Group plc:
cosec@convatec.com

Media: MediaRelations@convatec.com

Investor Relations: IR@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 2.2 Information disclosed under article 19 of the Market Abuse Regulation

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over 2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit <http://www.convatecgroup.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFIDTTIDIIE